



PATENT
Attorney Docket No.: 011823-004012US
Client Reference No.: 004012 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Co et al.

Application No.: 10/084,825

Filed: February 25, 2002

For: INCREASING ANTIBODY
AFFINITY BY ALTERING
GLYCOSYLATION OF
IMMUNOGLOBULIN VARIABLE
REGION

Examiner: Larry Helms

Art Unit: 1642

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

Applicant believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Joe Liebeschuetz
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
JOL:crf
60261100 v1



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/084,825		
		Filing Date	February 25, 2002		
		First Named Inventor	Co, Man Sung		
		Art Unit	1642		
		Examiner Name	Larry Helms		
Sheet	2	of	2	Attorney Docket Number	011823-004012US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AC	CO et al., "Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody," <u>Mol. Immunol.</u> , 30:1361 (1993).	
	AD	COLMA et al., "Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti-(1-6) dextran antibody," <u>Jour. Immunol.</u> , 162:2162 (1999).	
	AE	GALA et al., "V region carbohydrate and antibody expression," <u>Jour. Immunol.</u> , 172:5494 (2004).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.